NEWARK, Calif.–(BUSINESS WIRE)–Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology firm centered on progressive aesthetic and therapeutic choices, together with its investigational neuromodulator product, DaxibotulinumtoxinA for Injection, at the moment introduced new rent grants totaling an combination of 40,500 inducement restricted stock awards (“RSAs”) to 9 staff. The RSAs vest over 4 years, with 25% of the underlying shares vesting on every of the 4 anniversaries of the relevant vesting graduation date, topic to the brand new worker’s continued service relationship with Revance by the relevant vesting dates.
The Compensation Committee of Revance’s Board of Administrators authorized the awards as an inducement materials to the brand new staff’ employment in accordance with NASDAQ Itemizing Rule 5635(c)(4).
About Revance Therapeutics, Inc.
Revance Therapeutics, Inc. is a biotechnology firm centered on progressive aesthetic and therapeutic choices, together with its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a extremely purified botulinum toxin that doesn’t comprise human or animal-based elements. Revance has efficiently accomplished a Section three program for DaxibotulinumtoxinA for Injection in glabellar (frown) strains and is pursuing U.S. regulatory approval in 2020. Revance can be evaluating DaxibotulinumtoxinA for Injection within the full higher face, together with glabellar strains, brow strains and crow’s toes, in addition to in two therapeutic indications – cervical dystonia and grownup higher limb spasticity. To accompany DaxibotulinumtoxinA for Injection, Revance owns a novel portfolio of premium services and products for U.S. aesthetics practices, together with the unique U.S. distribution rights to the RHA® Assortment of dermal fillers, the primary and solely vary of FDA-approved fillers for correction of dynamic facial wrinkles and folds, and the HintMD fintech platform, which incorporates built-in sensible cost, subscription and loyalty digital companies. Revance has additionally partnered with Viatris to develop a biosimilar to BOTOX®, which might compete within the present short-acting neuromodulator market. Revance is devoted to creating a distinction by reworking affected person experiences. For extra info or to affix our group go to us at www.revance.com.
“Revance Therapeutics” and the Revance emblem are registered logos of Revance Therapeutics, Inc.
RHA resilient hyaluronic acid® and RHA® are logos of TEOXANE SA.
BOTOX® is a registered trademark of Allergan, Inc.